Carotuximab is under clinical development by Kairos Pharma and currently in Phase II for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to GlobalData, Phase II drugs for Metastatic Castration-Resistant Prostate Cancer (mCRPC) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Carotuximab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Carotuximab overview
Carotuximab (ENV-105) is under developmentfor the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer. The therapeutic candidate is administered through intravenous and intravitreal route. It is anti-endoglin. It is a human/murine chimeric IgG1 monoclonal antibody that inhibits angiogenesis and tumor growth with potential antiangiogenic and antineoplastic activities. It targets human endoglin (CD105). It was under development for treatment of wet age-related macular degeneration (AMD), epithelial ovarian cancer, angiosarcoma, fallopian tube cancer, primary peritoneal carcinoma, transitional cell carcinoma, HER2 negative metastatic breast cancer, progressive or recurrent glioblastoma multiforme, colorectal cancer, metastatic renal cell carcinoma, bladder cancer, metastatic castrate resistant prostate cancer, non-squamous non-small cell lung cancer, choriocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, non-metastatic breast cancer, cardiac fibrosis, acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (B-cell ALL).
Kairos Pharma overview
Kairos Pharma is focused on developing pipeline of therapeutics for cancer patients that reverse the inhibitory effects of cancer on the immune system. Kairos Pharma is headquartered in Los Angeles, California, the US.
For a complete picture of Carotuximab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
